Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1819-1830

  Moran, Gary P ^a   Sanglard, Dominique ^b   Donnelly, Samantha M ^a   Shanley, Diarmuid B ^a   Sullivan, Derek J ^a   Coleman, David C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GLYCOPROTEIN P;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE;

EID: 0031807122     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1819     Document Type: Article

References (43)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
3. Bennett, D. E., C. E. McCreary, and D. C. Coleman. 1998. Genetic characterisation of a phospholipase C gene from Candida albicans: presence of homologous sequences in Candida species other than C. albicans. Microbiology 144:55-72.
4. Boerlin, P., F. Boerlin-Petzold, C. Durussel, M. Addo, J.-L. Pagani, J.-P. Chave, and J. Bille. 1995. Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. J. Clin. Microbiol. 33:1129-1135.
5. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
6. Coleman, D. C., D. J. Sullivan, D. E. Bennett, M. C. Henman, G. P. Moran, H. J. Barry, and D. B. Shanley. 1997. The emergence of Candida dubliniensis: a novel Candida species associated with oral candidiasis in individuals infected with HIV and with AIDS. AIDS 11:557-567.
7. Fling, M. E., J. Kopf, A. Tamarkin, J. A. Gorman, H. A. Smith, and Y. Koltin. 1991. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet. 227:318-329.
8. Gallagher, P. J., D. E. Bennett, M. C. Henman, R. J. Russell, S. R. Flint, D. B. Shanley, and D. C. Coleman. 1992. Reduced azole susceptibility of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J. Gen. Microbiol. 138:1901-1911.
9. Genetics Computer Group. 1994. Program manual for the GCG package, version 8.0, September 1994. Genetics Computer Group, Madison, Wis.
10. Gilfillan, G. D., D. J. Sullivan, K. Haynes, T. Parkinson, D. C. Coleman, and N. A. R. Gow. 1998. Candida dubliniensis: phylogeny and putative virulence factors. Microbiology 144:829-838.
11. Goffeau, A., J. Park, I. T. Paulsen, J.-L. Jonniaux, T. Dinh, P. Mordant, and M. H. Saier, Jr. 1997. Multidrug-resistant transport proteins in yeast: complete inventory and phylogenetic characterisation of yeast open reading frames within the major facilitator superfamily. Yeast 13:43-54.
12. Higgins, D. G., and P. M. Sharp. 1998. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 73:237-244.
13. Hube, B., M. Monod, D. A. Schofield, A. J. P. Brown, and N. A. R. Gow. 1994. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol. Microbiol. 14:87-99.
14. Johnson, E. M., and D. W. Warnock. 1995. Azole drug resistance in yeasts. J. Antimicrob. Chemother. 36:751-755.
15. Klepser, M. E., E. J. Ernst, and M. A. Pfaller. 1997. Update on antifungal resistance. Trends Microbiol. 5:372-375.
16. Kyte, J., and R. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
17. Löffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. Lass-Flörl, and H. Einsele. 1997. Molecular analysis of cyp51 from fluconazole resistant Candida albicans isolates. FEMS Microbiol. Lett. 151:263-268.
18. McCullough, M., B. Ross, and P. Reade. 1995. Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus. J. Clin. Microbiol. 33:696-700.
19. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41: 617-623.
20. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
21. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.
22. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
23. Prasad, R., P. De Wergifosse, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterisation of a novel gene of Candida albicans. CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
24. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
25. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
26. Rodriguez-Tudela, J. L., and J. V. Martinez-Suárez. 1995. Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria. J. Antimicrob. Chemother. 35:739-749.
27. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory. Cold Spring Harbor, N.Y.
28. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
29. Sanglard, D. Unpublished data.
30. Sanglard, D., F. Ischer, L. Kogmans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
31. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterisation of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405-416.
32. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
33. Schoofs, A., F. C. Odds, R. Colebunders, M. Ieven, L. Wouters, and H. Goosens. 1997. Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob. Agents Chemother. 41:1625-1635.
34. Sullivan, D., D. Bennett, M. Henman, P. Harwood, S. Flint, F. Mulcahy, D. Shanley, and D. Coleman. 1993. Oligonucleotide fingerprinting of isolates of Candida species other than C. albicans and of atypical Candida species from human immunodeficiency virus-positive and AIDS patients. J. Clin. Microbiol. 31:2124-2133.
35. Sullivan, D., K. Haynes, J. Bille, P. Boerlin, L. Rodero, S. Lloyd, M. Henman, and D. Coleman. 1997. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 35:960-964.
36. Sullivan, D. J., and D. C. Coleman. 1998. Candida dubliniensis: characteristics and identification. J. Clin. Microbiol. 36:329-334.
37. Sullivan, D. J., T. J. Westerneng, K. A. Haynes, D. E. Bennett, and D. C. Coleman. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular characterisation of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 141:1507-1521.
38. Vazquez, J. A., A. Beckley, J. D. Sobel, and M. J. Zervos. 1991. Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J. Clin. Microbiol. 29:962-967.
39. Warnock, D. W. 1992. Azole drug resistance in Candida species. J. Med. Microbiol. 37:225-226.
40. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
41. White, T. C. 1997. Presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanostcrol 14α demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
42. Wickes, B. L., and R. Petter. 1996. Genomic variation in C. albicans. Curr. Top. Med. Mycol. 7:71-86.
43. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with hone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.